Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1992-11-12
2000-09-26
Cintins, Marianne
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, 514913, A61K 31215, A61K 3119
Patent
active
061243531
ABSTRACT:
The present invention provides a method of treating ocular hypertension which comprises applying to the eye an amount sufficient to treat ocular hypertension of a compound of formula (I) ##STR1## wherein the wavy line attachments indicate either alpha (.alpha.) or beta (.beta.) configuration; hatched lines indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration; the dashed bonds represent a single bond or a double bond which can be in the cis or trans configuration; X is selected from the group consisting of H, R or a pharmaceutically-acceptable cation, and R is an aliphatic hydrocarbon group of about 1 to about 6 carbon atoms; one of R.sub.1 and R.sub.2 is .dbd.O, --OH or an --O(CO)R.sub.4 group, and the other one is --OH or an --O(CO)R.sub.4 group or R.sub.1 is .dbd.O and R.sub.2 is H; R.sub.3 is --OH or --O(CO)R.sub.4, wherein R.sub.4 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or --(CH.sub.2).sub.n R.sub.5 wherein n is 0-10, and R.sub.5 is an aliphatic ring from about 3 to about 7 carbon atoms, or an aromatic or heteroaromatic ring; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan
patent: 5139491 (1992-08-01), Chan
AM. J. Physiol.,263(3,PT.2), H660-H663 1992 Banerjee, Mukul et al 'Effects of a novel prostaglandin, 8-epi-PGF2. alpha., in rabbit lung in situ'.
Prostaglandins, 44(2), 155-63 1992 Morrow, J.D. et al 'The F2-isoprostane, 8-epi-prostaglandin F2. alpha., a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist'.
Bito, L.Z., Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents; . Biological Protection with Prostaglandins, Cohen, M.M.; ed.; Boca Ratan, Fla, CRC Press, Inc., 1985, pp. 231-252.
Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents;"Applied Pharmacology in the Medical Treatment of Glaucomas, Drace, S.M. & Neufeld, A.H.eds., New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson, et. al., "Increases Uveoscleral Outflow," Invest. Opthalmol. Vis.Sci, 28 (suppl), 284, 1987.
Bito, L.Z., "Prostaglandins, Old concepts and New Perspectives," Arch. Ophthalmol 105, 1036, 1987.
Siebold, et.al., "Esterified prostaglandin shows 'potent' promise," Prodrug, May 3, 1989.
Allergan Sales Inc.
Baran Robert J.
Cintins Marianne
Fisher Carlos A.
Voet Martin A.
LandOfFree
Method of treating ocular hypertension with 8-epi prostaglandins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating ocular hypertension with 8-epi prostaglandins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating ocular hypertension with 8-epi prostaglandins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100744